The hypothesis is that an interaction between the ␤ I-like metal ion-dependent adhesion site (MIDAS) and an intrinsic ligand in the linker following the ␣ I domain, Glu-310, exerts a pull that activates the ␣ I domain. Individual mutation of ␣ L linker residue Glu-310 or ␤2 MIDAS residues Ala-210 or Tyr-115 to cysteine abolishes I domain activation, whereas the double mutation of ␣L-E310C with either ␤2-A210C or ␤2-Y115C forms a disulfide bond that constitutively activates ligand binding. The disulfide-bonded mutant is resistant to small molecule antagonists that bind to the ␤ I-like domain near its interface with the ␣ I domain and inhibit communication between these domains but remains susceptible to small molecule antagonists that bind underneath the I domain ␣7-helix and certain allosteric antagonistic antibodies. Thus, the ␣7-helix and its linker are better modeled as a pull spring than a bell rope. The results suggest that ␣L residue Glu-310, which is universally conserved in all I domain-containing integrins, functions as an intrinsic ligand for the ␤ I-like domain, and that when integrins are activated, the ␤ I-like MIDAS binds to Glu-310, pulls the spring, and thereby activates the ␣ I domain.
I
ntegrins are a large family of adhesion receptors that regulate cell migration and tissue organization and transduce signals bidirectionally across the plasma membrane. They are the most structurally complicated adhesion molecules yet known, with noncovalently associated ␣-and ␤-transmembrane subunits containing five and eight distinctive domains, respectively, in their extracellular segments. Half of vertebrate integrin ␣-subunits and all ␤-subunits contain von Willebrand factor-type A domains, termed inserted (I) and I-like domains, respectively (1) (2) (3) . Both I and I-like domains have an ␣͞␤-fold with a central ␤-sheet surrounded by ␣-helices and a metal ion-dependent adhesion site (MIDAS) at the C-terminal ends of the central ␤-strands, i.e., the ''top'' face (1, (4) (5) (6) . In integrins that lack I domains, I-like domains directly mediate ligand binding: a metal at the MIDAS coordinates to an acidic residue in the ligand (7) . In I domaincontaining integrins such as ␣ L ␤ 2 , the I domain binds the acidic residue of the ligand through its MIDAS (4, (8) (9) (10) , whereas the I-like domain regulates binding by the I domain (11) . However, the molecular mechanism of I domain regulation by the I-like domain remains unknown.
The I domain is inserted in the integrin ␣-subunit between blades 2 and 3 of the ␤-propeller domain (12) . The I domain C-terminal ␣7-helix and the linker connecting it to the ␤-propeller domain are crucial for regulation of ligand binding. Downward movement of the ␣7-helix activates the I domain (8, 9, (13) (14) (15) . Mutations in the ␣7-helix and linker may either activate or inactivate the I domain (16) (17) (18) (19) . A liganded crystal structure of integrin ␣ V ␤ 3 , which lacks an ␣ I domain, shows that the acidic Asp side chain of a ligand-mimetic peptide Arg-GlyAsp is bound to the MIDAS of the ␤ 3 I-like domain, whereas the Arg side chain binds to loops of the ␣ V ␤-propeller, at a site equivalent to where the I domain is inserted into the ␣ L ␤-propeller domain (6) . Because a Glu residue in the linker between the I and ␤-propeller domains corresponding to Glu-310 in ␣ L is absolutely conserved in all I domain-containing integrins, and mutation of this residue in ␣ L (16) or ␣ M (20) abolishes I domain activation, it previously has been proposed that Glu-310 might interact with the metal in the ␤ 2 MIDAS in a way that mimics ligand binding by integrins that lack I domains ( Fig. 1A) (1, 16, 20) . However, a large number of explanations are possible for the negative effect of mutation of ␣ L Glu-310, and no evidence for an interaction with the ␤ I-like domain has been presented. In this article, by constructing second-site revertant mutations (21), we test the hypothesis that when activated, the ␤ 2 I-like domain MIDAS binds ␣ L residue Glu-310 in the linker between the I domain and the ␤-propeller domain and exerts a downward pull on the ␣7-helix of the I domain that activates the I domain (Fig. 1 A) .
Materials and Methods
Cell Lines, Antibodies, and Small Molecule Inhibitors. cDNAs of wild-type ␣ L and ␤ 2 were inserted into pcDNA3.1͞Hygro(ϩ) or pcDNA3.1(ϩ) and used as the template for mutagenesis. The ␣ L and ␤ 2 mutations were generated by using QuikChange XL Site-Directed Mutagenesis Kit (Stratagene). All constructs were verified by DNA sequencing. 293T cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. K562 cells were transfected by electroporation and selected with 1 mg͞ml G418 (22) . mAbs to human ␣ L and ␤ 2 are as described (11) . mAbs m24 (23) and KIM127 (24) were kind gifts of N. Hogg (Imperial Cancer Research Fund, London) and M. Robinson (Celltech, Slough, U.K), respectively. mAbs were used as 10 g͞ml purified IgG or 1:200 ascites. LFA703 (25, 26) was kindly provided by Novartis Pharma (Basel). XVA143 (27) was synthesized according to example 345 of the patent (28) and was obtained from Paul Gillespie (Roche, Nutley, NJ) Cell Adhesion Assay. Binding of fluorescently labeled transfectants to immobilized intercellular adhesion molecule-1 (ICAM-1) was as described (22) . Briefly, soluble ICAM-1 (domains 1-5) was immobilized at 10 g͞ml on microtiter plates. Binding of the 293T transient transfectants to immobilized ICAM-1 was determined in 2.5% FBS͞L15 medium. Binding of K562 stable transfectants to immobilized ICAM-1 was determined in Hepes͞ NaCl͞Glucose͞BSA (20 mM Hepes, pH 7.5͞140 mM NaCl͞2 mg/ml glucose͞1% BSA) supplemented as indicated with diva-lent cations and DTT. After incubation at room temperature for 30 min, unbound cells were washed off and bound cells were quantitated (22) .
Binding of Soluble ICAM-1. Binding of soluble ICAM-1-IgA͞Fc fusion protein complexed with affinity-purified, FITC antihuman IgA was measured by immunofluorescence flow cytometry (29) .
Cell Surface Biotinylation and Immunoprecipitation. Cell surface biotinylation and immunoprecipitation were as described (29) .
Results

Design and Cell Surface Expression of ␣L␤2 Second-Site Reversion
Mutants. ␣ L -and ␤ 2 -subunits were coexpressed in transient 293T or stable K562 transfectants, and adhesion to ICAM-1 immobilized on substrates or binding to soluble multimeric fluorescent ICAM-1 was measured (Fig. 2) . Mutation ␣ L -E310C abolished binding to ICAM-1 similarly to ␣ L -E310A, confirming a crucial role for Glu-310 in I domain activation (Fig. 2 A) (16) . To search for a site in the ␤ 2 -subunit where a cysteine could be introduced that would suppress the ␣ L -E310C mutation by formation of an intersubunit disulfide bond, the liganded ␣ V ␤ 3 structure (7) was examined for a residue around the I-like domain MIDAS that was close to the loop between blade 2 and blade 3 of the ␤-propeller, where the I domain is inserted in ␣ L (12) . Metal coordinating residues and buried residues were excluded. By using these criteria, residue ␤ 2 -A210 was selected, which is in the MIDAS loop that bears the metal-coordinating residue Glu-212 (Fig. 1B) .
We expected that ␣ L -E310 would bind to the ␤ 2 MIDAS as part of a larger intersubunit interface, and that exposed residues in ␤ 2 MIDAS loops also would contribute to this interface. ␤ 2 -A210 is nearby the MIDAS coordinating residue ␤ 2 -E212, and we therefore hoped that the mutation ␤ 2 -A210C might by itself inactivate ␣ L ␤ 2 . Indeed, the ␤ 2 -A210C mutation abolished binding to ICAM-1 ( Fig. 2 A) , showing a crucial role for a non-metal-coordinating ␤ 2 MIDAS loop residue in ␣ L ␤ 2 activation and suggesting that residues in the vicinity of the ␤ 2 MIDAS, including ␤ 2 -Ala-210, might interact with the I domain Cterminal linker.
Formation of an Intersubunit Disulfide Bond Between ␣L-E310C and
␤2-A210C Constitutively Activates Integrin ␣L␤2. To directly test the hypothesis that an interaction between residues in the vicinity of ␣ L linker residue E310 and ␤ 2 MIDAS residue A210 activates ␣ L ␤ 2 , the ␣ L -E310C and ␤ 2 -A210C mutants were cotransfected. Despite the abolition of binding by the individual substitutions in the ␣ L -E310C͞␤ 2 and ␣ L ͞␤ 2 -A210C heterodimers, the ␣ L -E310C͞␤ 2 -A210C double mutant heterodimer was fully activated ( Fig. 2 A, C, and D) . By contrast, the ␣ L -E310A͞␤ 2 -A210C double mutant was inactive. Immunofluorescent flow cytometry showed all ␣ L -E310 and ␤ 2 -A210 single and double mutants were as well expressed as wild-type ␣ L ␤ 2 in both 293T and K562 transfectants (Fig. 2E , bottom line, and data not shown). These results demonstrate second-site reversion between mutations at residues ␣ L -E310 and ␤ 2 -A210 when each residue is mutated to cysteine. Immunoprecipitation from K562 transfectants and reducing and nonreducing SDS͞PAGE demonstrated that the ␣ L -E310C͞␤ 2 -A210C heterodimer, but not the wild-type ␣ L ␤ 2 heterodimer, is covalently linked with a disulfide bond (Fig. 2B) , with an efficiency of formation of 80%. ␤ I-like domains contain a specificity-determining loop with disulfide-bonded cysteines that locate Ϸ12 Å from the I-like MIDAS and 16 Å from ␤ 2 -A210 (7). To rule out any possible interaction with the engineered disulfide, these cysteines were mutated to Ala in the ␤ 2 -C169A͞C176A mutant. Although ␣ L ͞␤ 2 -C169A͞C176A͞ A210C was inactive, ␣ L -E310C͞␤ 2 -C169A͞C176A͞A210C was constitutively active in binding to ICAM-1 and bound as well as ␣ L -E310C͞␤ 2 -A210C and activated wild-type ␣ L ␤ 2 after correc- It is hypothesized that ␣L-Glu-310 acts as an intrinsic ligand that binds to the ␤2-subunit I-like domain MIDAS and, thus, axially displaces the I domain ␣7-helix in the C-terminal direction, reshapes the ␤6-␣7 loop, and activates the ␣L I domain MIDAS (1, 16, 20) . C-terminal axial displacement of the ␣7-helix and ␤6-␣7 loop reshaping is known to result in a 10,000-fold increase in affinity for ligand of the ␣L I domain (9) . Swing-out of the hybrid domain is depicted as demonstrated for ␣V␤3 and ␣5␤1 (35, 36) . (B) Stereo diagram of the MIDAS loops of the ␤2 and ␤3 I-like domains (yellow) and the W2-W3 loop of the ␣V ␤-propeller domain (blue). The structure shown is that of liganded ␣V␤3 (6); all side chains shown are identical in ␤2 and ␤3, and numbering is that of ␤2. Mutated residues are shown in green; MIDAS-coordinating residues are shown in yellow; O atoms are red. The ligand-induced metal-binding site (LIMBS), MIDAS, and adjacent to MIDAS (ADMIDAS) metal ions are gold, silver, and gold spheres, respectively, from left to right.
tion for the lower expression of heterodimers containing the ␤ 2 -C169A͞C176A mutation (Fig. 2E) . Furthermore, ␣ L -E310C͞ ␤ 2 -C169A͞C176A͞A210C formed a disulfide-linked heterodimer (data not shown).
Suppression between the ␣ L -E310C and ␤ 2 -A210C mutations did more than restore wild-type ligand binding, it also resulted in constitutive activation. In 293T transfectants in the absence of activation, the ␣ L -E310C͞␤ 2 -A210C double mutant was more active than wild-type ␣ L ␤ 2 and appeared maximally activated, as shown by lack of further activation by CBR LFA-1͞2 mAb to the ␤ 2 I-EGF3 domain and comparison to ␣ L ␤ 2 with a mutant high-affinity (HA) ␣ L I domain (Fig. 2 A) . In K562 transfectants, (D-F) . Binding was assayed in Hepes͞NaCl͞glucose͞BSA (K562 transfectants) or 2.5% FBS͞L15 medium (293T transfectants) supplemented with 1 mM CaCl 2͞1 mM MgCl2, 2 mM MgCl2, or 2 mM MnCl2 plus 10 g͞ml CBR LFA-1͞2 or 2 mM DTT as indicated at room temperature. In E, binding of ICAM-1 by different 293T transfectants was normalized to their ␣L␤2 cell surface expression by multiplying by the ratio of the specific mean fluorescence intensity (MFI) of TS2͞4 mAb binding to wild-type and mutant ␣L␤2. MFI of TS2͞4 mAb before subtraction of the MFI of untransfected cells to obtain specific MFI is shown in the bottom row of E. Binding by the mock transfectant was not normalized.
wild-type ␣ L ␤ 2 was inactive under basal conditions in Ca 2ϩ ͞ Mg 2ϩ , whereas the ␣ L -E310C͞␤ 2 -A210C double mutant was maximally active in Ca 2ϩ ͞Mg 2ϩ both in adhesion assays and in binding of soluble multimeric ICAM-1 ( Fig. 2 C and D) . (Fig. 2F) .
DTT was used to reduce the disulfide bond. Although reduction with 10 mM DTT at 37°C can activate ␤ 2 integrins (8, 30), 2 mM DTT at room temperature did not affect binding of wild-type ␣ L ␤ 2 to immobilized or soluble ICAM-1 (Fig. 2 C, D,  and F) . However, 2 mM DTT abolished the binding of ␣ L -E310C͞␤ 2 -A210C to ICAM-1 (Fig. 2 C, D, and F) . Ligand binding by wild-type ␣ L ␤ 2 , but not DTT-treated ␣ L -E310C͞␤ 2 -A210C, was activated by CBR LFA-1͞2 mAb and Mn 2ϩ ( Fig. 2  C, D, and F) . The inability of DTT-treated ␣ L -E310C͞␤ 2 -A210C to bind ligand agrees with the finding above that both ␣ L -E310C͞␤ 2 and ␣ L ͞␤ 2 -A210C heterodimers failed to bind ligand. We conclude that (i) in the active conformation of ␣ L ␤ 2 , residues ␣ L -310 and ␤ 2 -210 are in sufficiently close proximity to form a disulfide bond when mutated to cysteine; (ii) disulfide bond formation is required for second-site reversion between the ␣ L -E310C and ␤ 2 -A210C mutations; and (iii) formation of a disulfide bond between these residues constitutively activates the ␣ L I domain. Wild-type ␣L␤2 in K562 transfectants was activated by preincubation with mAb CBR LFA-1͞2. Binding to soluble, multimeric ICAM-1 in medium containing 1 mM CaCl 2 and 1 mM MgCl2 was in the presence of the indicated mAb. Results are means Ϯ SD of three experiments. HA, high-affinity I domain mutant (8) . *The epitope spans the linker including ␣L-E310C. Binding of CBR LFA-1͞1 to the ␣L-E310C͞␤2-A210C and HA mutants was Ϸ50% of binding to wild-type ␣L␤2 (8) . All other mAbs bound to ␣L-E310C͞␤2-A210C, HA ␣L␤2, and wild-type ␣L␤2 equally well (data not shown). blocked binding of the ␣ L -E310C͞␤ 2 -A210C mutant but not the HA ␣ L ␤ 2 mutant to ICAM-1, suggesting that the ␣ L -E310C͞␤ 2 -A210C mutation does not irreversibly activate the I domain. mAbs to the ␤ 2 I-like domain inhibit ICAM-1 binding allosterically, as shown by inhibition of wild-type but not HA ␣ L ␤ 2 (Table 1 ) (11). Interestingly, mAbs May.017 and MHM23, which bind to the specificity-determining loop of the I-like domain, which locates in or very near to the ␣ I͞␤ I-like interface, partially inhibited ligand binding by ␣ L -E310C͞␤ 2 -A210C (Table  1) . By contrast, mAbs that bind distal to this interface, to the ␤ 2 I-like domain ␣1-and ␣7-helices, did not inhibit ␣ L -E310C͞␤ 2 -A210C ( Table 1) . The mechanism of activation by the disulfide between the ␣ L I linker and the ␤ 2 I-like MIDAS was investigated further with representatives of two distinct classes of small molecule antagonists, LFA703 and XVA143. Both are allosteric antagonists, as shown by lack of inhibition of HA ␣ L ␤ 2 (29) . LFA703 binds to the hydrophobic pocket underneath the ␣7-helix of the ␣ L I domain and stabilizes the low-affinity, closed conformation of the I domain (25, 26) . ␣ L -E310C͞␤ 2 -A210C was as sensitive to inhibition by LFA703 as wild-type ␣ L ␤ 2 (Fig. 3A) . XVA143 binds to the MIDAS of the ␤ 2 I-like domain and blocks its ability to communicate activation to the ␣ I domain (27, 29) . The ␣ L -E310C͞␤ 2 -A210C mutant was totally resistant to inhibition by XVA143 (Fig. 3B) .
Susceptibility to Small Molecule Antagonists and
The global conformation of the ␣ L -E310C͞␤ 2 -A210C mutant was examined with the m24 mAb to an activation epitope on the ␤ 2 I-like domain (11, 23, 31) and the KIM127 mAb to an epitope on the ␤ 2 I-EGF2 domain that is buried in the bent integrin conformation and exposed in the extended conformation (32, 33) . The disulfide connecting the ␣ L I domain linker to the ␤ 2 I-like MIDAS did not induce exposure of either epitope, suggesting that the extended conformation is not induced and that the I-like domain remains in an inactive conformation (Fig. 3 C  and D) . This finding is as expected, because unlike coordination of ␣ L -Glu-310 with the ␤ 2 MIDAS metal, the disulfide bond is not expected to alter MIDAS coordination and ␤ 2 I-like domain conformation. Similarly, mutationally stabilizing the ␣ L I domain in the high-affinity conformation with the HA ␣ L ␤ 2 mutant does not lead to ␤ 2 I-like domain activation or global conformational change (11) . Nonetheless, the active conformation of the ␤ 2 I-like domain detected by m24 mAb and the extended integrin conformation detected by KIM127 mAb were induced in the ␣ L -E310C͞␤ 2 -A210C mutant by Mn 2ϩ and by XVA143 (Fig. 3 C  and D) . This finding shows that the ␣ L -E310C͞␤ 2 -A210C mutant is capable of undergoing global conformational change and binds to XVA143 despite lack of inhibition of ligand binding by XVA143.
Another Second-Site Reversion ␣L␤2 Mutant That also Constitutively Binds ICAM-1. To obtain further evidence for an interaction of ␣ L -Glu-310 with the ␤ 2 MIDAS, we mutated residue ␤ 2 -Tyr-115 (Fig. 1B) . Tyr-115 is located between the two Ser residues in the MIDAS DXSYS sequence motif. Ala-210 and Tyr-115 locate opposite one another on either side of the MIDAS metal ion (Fig. 1B) . ICAM-1 binding by ␣ L ␤ 2 was reduced by the ␤ 2 -Y115A mutation and totally abolished by the ␤ 2 -Y115C mutation (Fig.  4A) . The double mutant ␣ L -E310C͞␤ 2 -Y115C constitutively bound ICAM-1, exactly as observed for the ␣ L -E310C͞␤ 2 -A210C mutant (Fig. 4A) . Moreover, immunoprecipitation from 293T transfectants and SDS͞PAGE demonstrated that the ␣ L -E310C and ␤ 2 -Y115C subunits were covalently linked together with a disulfide bond, with an efficiency of formation of 63% (Fig. 4B) . Ligand binding by ␣ L -E310C͞␤ 2 -Y115C was abolished by DTT reduction, demonstrating that the intersubunit disulfide bond was indispensable for ligand-binding activity (Fig. 4A) .
Discussion
To the classical technique of second-site reversion mutations (21), we have added the twists of disulfide bond formation and mutations that activate function as well as suppress loss of function. The ␣ L mutation E310C and the ␤ 2 mutations A210C and Y115C individually abolish activation of ligand binding by ␣ L ␤ 2 , but use of the ␣ L mutation in combination with either of the ␤ 2 mutations constitutively induces ␣ L ␤ 2 activation. The formation of the intersubunit disulfide bonds and their requirement for activation of ligand binding directly demonstrate interaction between these regions of ␣ L and ␤ 2 in the active integrin conformation. The ␤ I-like MIDAS metal ion is centered immediately between residues Ala-210 and Tyr-115, only 5 Å from their C␣ atoms. The activating crosslinks to these residues strongly support the hypothesis that interaction between ␣ L residue Glu-310 and the metal of the ␤ 2 I-like domain MIDAS induces the high-affinity conformation of the ␣ L I domain. Glu-310 is the only acidic residue in the ␣ L I domain ␣7-helix or its linker to the ␤-propeller domain that is conserved in all integrin I domains, and mutation of the other ␣ L acidic residues in the same polypeptide segment, Glu-301 (16), Asp-316, and Glu-323 (data not shown) does not abolish ␣ L ␤ 2 activation. In integrins that lack I domains, the ␤ I-like domain MIDAS metal ion when activated directly coordinates an acidic residue in the ligand, e.g., the Asp of the Arg-Gly-Asp (RGD) motif common to many integrin ligands (7) . Our data strongly support the concept that integrins that contain I domains are activated by a similar interaction in which an intrinsic ligand-like residue, ␣ L -Glu-310, rather than an extrinsic ligand, binds to a metal ion at the ␤-subunit I-like MIDAS.
Receptor-ligand-like interaction between neighboring domains͞subunits is a previously uncharacterized mechanism for signal transmission in the extracellular environment and in adhesion molecules and may turn out to have parallels in the diverse range of pro-and eukaryotic intracellular enzymes and extracellular recognition molecules in which von Willebrand factor type A, i.e., I domains, are present (34) . ␣ I domains appear in integrins late in metazoan evolution, whereas ␤ I-like domains are present in all integrins, including those in Porifera, Drosophila, and Caenorhabditis elegans. Binding of I-like domains to an intrinsic ligand in the linker following the I domain must have evolved when I domains became inserted in integrin ␣-subunits, to enable regulated binding to an extrinsic ligand to be transferred from the ␤ I-like domain to the ␣ I domain.
Our study provides insight into the mechanics of the linkage between ␤ I-like and ␣ I domains. Movement of residue ␣ L -310 to a position near the ␤ 2 I-like MIDAS is sufficient to pull down the ␣7-helix, reshape the ␤6-␣7 loop, and activate the ␣ L I domain. The conformation of the ␤6-␣7 loop, but not that of the ␣7-helix, is important for transducing conformational change to the ␣ I MIDAS (9) . Allosteric inhibition of ␣ L -E310C͞␤ 2 -A210C by certain mAbs to the ␣ L and ␤ 2 I-like domains and LFA703 shows that the segment connecting the ␤6-␣7 loop (␣ L residue Ϸ293) to ␣ L residue 310 remains elastic. The connecting segment thus should be viewed as a pull spring rather than a bell rope or connecting rod. A pull spring, but not the other two types of mechanical connections, has the important feature that it would enable the ␤6-␣7 loop to assume three ratchet positions, as recently observed for the closed, intermediate, and open conformations of the ␣ L I domain, which have low, intermediate, and high affinity for ICAM-1, respectively (9).
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